Month: September 2025

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,...

The Global PAD Association has presented the 2025 Walking As Therapy Breakthrough Research of the Year award to The STRIDE Trial Research Team led by Dr. Marc P. Bonaca

Rutgers Robert Wood Johnson Medical School Study Published in JAMA Confirms Butterfly-Enabled POCUS Program Heavily Focused on LUNG US with AI Assistance Reduces Stay and Cost

A QI evaluation of a Butterfly-enabled POCUS program—centered on lung ultrasound for pulmonary congestion and assisted by an AI B-line...

error: Content is protected !!